M. Terashima

发表

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer

R. Kaiser, K. Azuma, I. Okamoto, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kaoru Tanaka, K. Azuma, I. Okamoto, 2013, Cancer Chemotherapy and Pharmacology.

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

Y. Nishimura, M. Fukuoka, K. Azuma, 2013, Investigational New Drugs.

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

M. Nishio, T. Tamura, H. Xiong, 2014, Cancer Chemotherapy and Pharmacology.

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical lung cancer.

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

J. Sakamoto, N. Masuda, T. Satoh, 2013, Breast Cancer.

Lack of dose dependency for radiation pneumonitis after chemoradiotherapy with the use of tomotherapy for lung cancer

K. Shibuya, T. Tada, K. Ishii, 2022, Nagoya journal of medical science.

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

K. Takayama, J. Uchino, M. Hibino, 2022, JTO clinical and research reports.

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

M. Fukuoka, Hirokazu Watanabe, T. Taguchi, 2009, Clinical Cancer Research.

Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study

N. Saijo, M. Fukuoka, T. Satoh, 2007 .

Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan

M. Fukuoka, T. Satoh, Y. Hasegawa, 2007 .

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

R. Kaiser, K. Nishio, T. Satoh, 2010, Molecular Cancer Therapeutics.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

M. Fukuoka, K. Tamura, M. Takada, 2007, Cancer research.

Molecular Cancer apeutics cular Medicine in Practice se I Safety , Pharmacokinetic , and Biomarker Study of F 1120 , an Oral Triple Tyrosine Kinase Inhibitor in Ther ients with Advanced Solid Tumors

R. Kaiser, T. Satoh, A. Tsuya, 2010 .

I Safety , Pharmacokinetic , and Biomarker Study of F 1120 , an Oral Triple Tyrosine Kinase Inhibitor in Ther ients with Advanced Solid Tumors

R. Kaiser, T. Satoh, A. Tsuya, 2010 .

Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer

M. Satouchi, Kaoru Tanaka, S. Morita, 2013, Cancer.

Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer

M. Terashima, Y. Takeyasu, Y. Yamanaka, 2024, Cancers.